2024-03-29T01:44:42Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1249572021-11-22T12:48:56Zcom_10261_105com_10261_1com_10261_22col_10261_358col_10261_275
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy
Pernía, Olga
Cortés-Sempere, María
Macías, María-Teresa
Ibáñez de Cáceres, Inmaculada
Instituto de Salud Carlos III
European Commission
Hypermethylation
IGFBP-3
IGFIR/AKT
NSCLC
Radiotherapy
Olga Pernía et al.
© 2014 Taylor & Francis Group, LLC. The methylation status of the IGFBP-3 gene is strongly associated with cisplatin sensitivity in patients with non-small cell lung cancer (NSCLC). In this study, we found in vitro evidence that linked the presence of an unmethylated promoter with poor response to radiation. Our data also indicate that radiation might sensitize chemotherapy-resistant cells by reactivating IGFBP-3-expression through promoter demethylation, inactivating the PI3K/AKT pathway. We also explored the IGFBP-3 methylation effect on overall survival (OS) in a population of 40 NSCLC patients who received adjuvant therapy after R0 surgery. Our results indicate that patients harboring an unmethylated promoter could benefit more from a chemotherapy schedule alone than from a multimodality therapy involving radiotherapy and platinum-based treatments, increasing their OS by 2.5 y (p =.03). Our findings discard this epi-marker as a prognostic factor in a patient population without adjuvant therapy, indicating that radiotherapy does not improve survival for patients harboring an unmethylated IGFBP-3 promoter.
2015-11-12T13:47:23Z
2015-11-12T13:47:23Z
2014-12-06
2015-11-12T13:47:24Z
artículo
Epigenetics : official journal of the DNA Methylation Society 9(11): 1446-1453 (2014)
http://hdl.handle.net/10261/124957
10.4161/15592294.2014.971626
http://dx.doi.org/10.13039/501100004587
http://dx.doi.org/10.13039/501100000780
25482372
eng
http://dx.doi.org/10.4161/15592294.2014.971626
Sí
closedAccess
Landes Bioscience